Valeant Pharmaceuticals International (VRX) Given a $16.00 Price Target at Goldman Sachs

Roman Schwartz
May 15, 2018

Goldman Sachs Group reported 3.43 million shs.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) received a $16.00 price objective from Goldman Sachs in a report issued on Tuesday. (NYSE:VRX). Keybank Natl Association Oh holds 0% or 10,000 shs. Valeant Pharmaceuticals International has a 1-year low of $10.57 and a 1-year high of $24.43. (NYSE:VRX). Valley National Advisers Inc reported 599 shares. 34,500 are owned by Diamond Hill Mgmt. Winslow Evans Crocker Inc holds 0.03% or 4,000 shares. 16,738 are held by Cohen Klingenstein Limited Co. Finally, Zacks Investment Research downgraded Valeant Pharmaceuticals International from a "hold" rating to a "strong sell" rating in a research note on Saturday, January 13th. After this purchase, 106,062 common shares of VRX are directly owned by the insider, with total stake valued at $1,926,086. Bnp Paribas Arbitrage Sa has 70,687 shares for 0% of their portfolio. (NYSE:VRX) for 2,070 shares. Greatmark Prtnrs stated it has 28,350 shares. Valeant Pharmaceuticals International, Inc.

Since March 8, 2018, it had 3 insider buys, and 0 sales for $876,370 activity.

In the transaction dated March 06, 2018, the great number of shares disposed came courtesy the Director; Paulson John disposed a total of 7,066,629 shares at an average price of $15.4, amounting to approximately $108,826,087.

In other Valeant Pharmaceuticals International news, Director John Paulson purchased 7,066,629 shares of Valeant Pharmaceuticals International stock in a transaction dated Tuesday, March 6th.

VRX has been the topic of several recent research reports. Valeant Pharmaceuticals International, Inc. Rating Scale; where 1.0 rating mean Strong Buy, 2.0 rating signifies Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. After all, it was only in 2010 that beleaguered pharma firm Biovail took over Valeant and assumed its name. Until that time, the Company will continue to trade on the New York Stock Exchange and Toronto Stock Exchange under its present symbol, VRX. Given a positive discrepancy of 22.91% between return and cost, this indicates that Valeant Pharmaceuticals International pays less for its capital than what it generates in return, which is a sign of capital efficiency.

Rage 2 Announcement Video Reveals a Colorful Post-Apocalypse
They started by tweeting various pictures that seemed innoculous, at first, but held a secret many didn't notice at first. The gameplay reveal will be coming tomorrow, but in the meantime be sure to check the insane announcement trailer below.

Want to see what other hedge funds are holding VRX?

Valeant Pharmaceuticals International (TSE:VRX) (NYSE:VRX) last announced its quarterly earnings data on Wednesday, February 28th. On Monday, December 4 the firm has "Hold" rating by BTIG Research given. Mizuho upgraded Valeant Pharmaceuticals International, Inc. On Monday, February 26 the firm has "Hold" rating by Canaccord Genuity given. On Friday, January 19 the stock rating was maintained by Cantor Fitzgerald with "Buy".

A number of equities analysts have issued reports on VRX shares. The titles are as follows: "Valeant: Endgame" brought out on May 08, 2018, "Salix FDA Win Boosts Valeant Stock Before Earnings" on May 07, 2018, "3 Dividend ETF Ideas To Start Your Week" with a publish date: May 08, 2018, "36 Stocks Moving In Tuesday's Mid-Day Session" and the last "4 Top Stock Trades for Wednesday Morning" with publication date: May 08, 2018. With approx. 778.85M shares in outstanding, the company has a market cap of $72.09B as per the current valuation. VRX is uptrending and has moved 42.00% since May 8, 2017.

The S&P 500 index rose 9.21 points, or 0.3 percent, to 2,672.63.

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices.

PEG ratio or Price/Earnings-Growth ratio is an attempt to normalize the P/E ratio with the expected earnings growth rate of the company. The firm operates through three divisions: Bausch + Lomb/International, Branded Rx, and U.S.2.89 is the P/E ratio.

Other reports by

Discuss This Article